yes iv) Octaplex 2.12 Lipid-Regulating Drugs Remain on Remove Supporting formulary from Information formulary Simvastatin Tablets yes Atorvastatin Tablets yes Pravastatin Tablets yes Ezetimibe Tablets Limited Discuss clinical with value, but clinical coming off lead and patent propose it soon becomes therefore non will be formulary cheaper Keep as red- restricted - Rosuvastatin Tablets working going on about changing about changing patients from rosuvastatin to atorvastatin – propose green restricted yes Bezafibrate Tablets Bezafibrate MR Tablets yes Colestyramine Sachets yes Fish oils (Maxepa) Capsules Gemfibrozil Tablets, Capsules Nicotinic Acid Tablets yes Anootate Alirocumab Pre-Filled Pen 75 mg only () has high costs
iv) Octaplex yes 2.12 Lipid-Regulating Drugs Remain on formulary Remove from formulary Supporting Information Simvastatin Tablets yes Atorvastatin Tablets yes Pravastatin Tablets yes Ezetimibe Tablets Limited clinical value, but coming off patent soon therefore will be cheaper Discuss with clinical lead and propose it becomes non formulary Rosuvastatin Tablets Keep as red- working going on about changing about changing patients from rosuvastatin to atorvastatin – propose green restricted restricted - Bezafibrate Tablets yes Bezafibrate MR Tablets yes Colestyramine Sachets yes Fish oils (Maxepa) Capsules Gemfibrozil Tablets, Capsules Nicotinic Acid Tablets Alirocumab Pre-Filled Pen 75 mg only () yes Anootate has high costs
Chapter-2-apc-decisions.docx